{ "ProductData": { "ID": "RTD000910", "ProductType": "Others", "BrandName": "FITC anti-C3 Primary Antibody", "ProductNameAddition": "", "RegulatoryDisclaimer1": "For in vitro diagnostic use.", "DisclaimerGroup1": "IVD", "RegulatoryDisclaimer2": null, "DisclaimerGroup2": null, "RegulatoryDisclaimer3": null, "SampleType": [ "Frozen tissue" ], "LicenseDisclaimers": [ ], "RelatedLinks": "", "Clone": "", "ControlTissue": [ "Frozen, Kidney or Skin from Lupus Cases Containing C3 Deposits" ], "ISOtypes": "", "Species": [ "Goat" ], "StainLocalization": [ "" ], "ProductNameGlobal": "C3 Primary Antibody FITC" }, "ProductImageDetails": { "ImagePath": "https://pim-media.roche.com/Images/Product_RTD000910_im_en.jpg", "ImageType": "Image main" }, "Product2Taxonomy": { "Product2TaxonomyReferences": [ { "StructureSystemIdentifier": "Product_Grouping", "StructureSystemName": "Product Grouping", "NodeID": "05-0002", "StructureNodeStatus": "Active", "NodeName": "IHC Primary Antibodies" }, { "StructureSystemIdentifier": "OWP_Techniques", "StructureSystemName": "Techniques", "NodeID": "073-00", "StructureNodeStatus": "Active", "NodeName": "Immunohistochemistry (IHC)" }, { "StructureSystemIdentifier": "Lab_Type", "StructureSystemName": "Lab Types", "NodeID": "080-00", "StructureNodeStatus": "Active", "NodeName": "Pathology Lab" }, { "StructureSystemIdentifier": "Disease_Areas", "StructureSystemName": "Disease Areas", "NodeID": "38-00-00", "StructureNodeStatus": "Active", "NodeName": "Skin cancer" }, { "StructureSystemIdentifier": "Product_Solutions", "StructureSystemName": "Product Solutions", "NodeID": "010", "StructureNodeStatus": "Active", "NodeName": "Histopathology" }, { "StructureSystemIdentifier": "Applications", "StructureSystemName": "Applications", "NodeID": "99-00-00", "StructureNodeStatus": "Inactive", "NodeName": "" }, { "StructureSystemIdentifier": "Pathogens", "StructureSystemName": "Pathogens", "NodeID": "99-00-00", "StructureNodeStatus": "Inactive", "NodeName": "" }, { "StructureSystemIdentifier": "Health_Topics", "StructureSystemName": "Health Topics", "NodeID": "22-00-00", "StructureNodeStatus": "Active", "NodeName": "Dermatology" }, { "StructureSystemIdentifier": "OWP_Product_Types", "StructureSystemName": "Product Types", "NodeID": "15-000-00", "StructureNodeStatus": "Active", "NodeName": "Primary Antibody" }, { "StructureSystemIdentifier": "OWP_Family", "StructureSystemName": "Product Families", "NodeID": "080", "StructureNodeStatus": "Active", "NodeName": "BenchMark" } ] }, "Product2Materials": { "P2MaterialReferences": [ { "MaterialNum": "05267978001", "MaterialDescription": "FITC ANTI-C3 PRIMARY ANTIBODY", "RegisteredProductName": "FITC anti-C3 Primary Antibody", "GTIN": "04015630971459", "ProductCategoryText": "Reagents, kits", "OldMaterialNumber": "760-2686", "PackSizePIM360": "50 tests", "PackSizeDescPIM360": "Not Available", "MaterialAnnotation": "", "ReadyForUse": "true", "OrderInformation": "" } ] }, "Product2Products": { "Product2ProductReference": [ { "ProductID": "INS_2099", "BrandName": "BenchMark ULTRA", "ProductNameAddition": "", "ReferenceType": "Instrument", "Classification": [ { "IdentifierofStructureSystem": "1", "NameofStructureSystem": "GPCH", "StructureNodeID": "2300", "StructureGroupPath": "Histology->Systems / Digital Products->Advanced Staining->BenchMark ULTRA", "StructureGroupName": "BenchMark ULTRA", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "OWP_Product_Types", "NameofStructureSystem": "Product Types", "StructureNodeID": "10-000-00", "StructureGroupPath": "Analyzer Instruments and Systems", "StructureGroupName": "Analyzer Instruments and Systems", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "OWP_Family", "NameofStructureSystem": "Product Families", "StructureNodeID": "080", "StructureGroupPath": "BenchMark", "StructureGroupName": "BenchMark", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "Lab_Type", "NameofStructureSystem": "Lab Types", "StructureNodeID": "080-00", "StructureGroupPath": "Pathology Lab", "StructureGroupName": "Pathology Lab", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "Product_Solutions", "NameofStructureSystem": "Product Solutions", "StructureNodeID": "010", "StructureGroupPath": "Histopathology", "StructureGroupName": "Histopathology", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "OWP_Techniques", "NameofStructureSystem": "Techniques", "StructureNodeID": "073-00", "StructureGroupPath": "Immunohistochemistry (IHC)", "StructureGroupName": "Immunohistochemistry (IHC)", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "OWP_Techniques", "NameofStructureSystem": "Techniques", "StructureNodeID": "075-00", "StructureGroupPath": "In situ Hybridization (ISH)", "StructureGroupName": "In situ Hybridization (ISH)", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "Applications", "NameofStructureSystem": "Applications", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "Disease_Areas", "NameofStructureSystem": "Disease Areas", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "Pathogens", "NameofStructureSystem": "Pathogens", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "Health_Topics", "NameofStructureSystem": "Health Topics", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" } ] } ] }, "ProductSpec": [ { "ProductSpecVariant": { "Chapters": [ { "Name": "Storage Conditions (Product)", "Value": "Store at 2-8°C. Do not freeze.", "Language": "en", "Country": "XG", "Code": "Storage Conditions (Product)" }, { "Name": "Content", "Value": "FITC anti-C3 contains sufficient reagent for 50 tests.

One5 mL dispenser of FITC anti-C3; contains approximately 440 µg (88 µg/mL) of a goat polyclonal antibody directed against human C3. The antibody is diluted in a tris based buffer containing carrier protein and preservative.
Total protein concentration of the reagent is approximately 0.5 mg/mL.", "Language": "en", "Country": "XG", "Code": "Content" }, { "Name": "Intended Use", "Value": "This antibody is intended for in vitro diagnostic (IVD) use.

Ventana^® Medical Systems’ (Ventana) FITC anti-C3 (complement 3) Primary Antibody is a goat derived polyclonal antibody labeled with fluorescein and specifically directed against human C3. This reagent should be used in conjunction with a panel of antibodies to aid in the identification of complement 3 in C3 target tissue (e.g., in the diagnosis of renal or dermal pathologies). FITC anti-C3 is intended for laboratory use to qualitatively stain sections of frozen tissue on a Ventana automated slide stainer.

The clinical interpretation of any staining, or the absence of staining, must be complemented by morphological studies and evaluation of proper controls. Evaluation must be made by a qualified pathologist within the context of the patient’s clinical history and other diagnostic tests.", "Language": "en", "Country": "XG", "Code": "Intended Use" }, { "Name": "Background Information", "Value": "Fluorescent antibodies have been used to detect specific antigens in cells or tissue for over 40 years.¹ An informative overview of the use of FITC conjugated antibodies as effective and specific immunofluorescent markers for cellular antigens may be found in Faulk and Humans.² Use of the immunofluorescence technique has resulted in an increased overall understanding of renal,³ and dermal⁴ pathologies.
The significance of the involvement of C3 in the complement system is reviewed by Ruddy.⁵ Human complement C3 has been previously visualized in skin using immunofluorescence.⁶ Observation of the presence or absence of C3 in conjugation with immunoglobulins is instrumental in the diagnosis of renal pathologies.⁷ FITC anti-C3 contains a goat polyclonal antibody raised against purified human C3. The antibody is obtained through purification of the goat gamma globulin fraction, followed by reaction with fluorescein isothiocyanate to produce a fluorescein to protein ratio of approximately 3–6 mol/mol. The excess dye is then removed by dialysis and the conjugated globulin is further fractionated on DEAE cellulose to remove over and under labeled protein.⁸ Anti-C3 binds specifically with human C3 and exhibits no reactivity with complement components C4-C9 or serum proteins.

1. Coons AH, Melvin H. Localization of Antigen in Tissue Cells. (II). Improvements in a Method for Detection of Antigen by Means of Flourescent Antibody. Albert & Kaplan. 1-13, 1950.
2. Faulk WP, Hijmans W. Recent developments in immunofluorescence. Prog Allergy.16:9-39, 1972.
3. McCluskey RT. The value of immunofluorescence in the study of human renal disease. J Exp Med. Sep 1;134(3):Suppl:242s+, 1971.
4. Wick MR, Ritter JH, Humphrey PA, Swanson PE. Immunopathology of nonneoplastic skin disease: a brief review. Am J Clin Pathol. Apr;105(4):417-29, 1996.
5. Ruddy S. Chemistry and biologic activity of the complement system. Transplant Proc. Mar; 6(1):1-7, 1974.
6. Dovezenski N, Billetta R, Gigli I. Expression and localization of proteins of the complement system in human skin J Clin Invest. Nov; 90(5):2000-12, 1992.
7. Leber PD, McCluskey RT. Complement and the immunohistology of renal disease. Transplant Proc. Mar; 6(1):67-76, 1974.
8. Wood BT, Thompson SH, Goldstein G. Fluorescent antibody staining. 3. Preparation of fluorescein-isothiocyanate-labeled antibodies. J Immunol. Aug; 95(2):225-9, 1965.", "Language": "en", "Country": "XG", "Code": "Background Information" }, { "Name": "Principle", "Value": "FITC anti-C3 may be used as the primary antibody for immunohistochemical staining of frozen tissue sections. In general, immunohistochemical staining allows the visualization of antigens via the sequential antibody) to the antigen, a secondary antibody application of a specific antibody (primary (link antibody) to the primary antibody, an enzyme complex and a chromogenic substrate with interposed washing steps. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. For FITC direct labeled antibodies, the fluorochrome is linked to the primary antibody and therefore no secondary antibody or chromogenic detection step is required. The primary antibody binds specifically to the target antigen and can then be visualized. Results are interpreted using a fluorescent microscope with the appropriate filter set and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.

FITC anti-C3 is optimally diluted for use with Ventana automated slide stainers. Each step in the staining protocol includes incubation for a precise time at a specific temperature. At the end of each incubation step, the sections are rinsed by the Ventana automated slide stainer to stop the reaction and remove unbound material that would hinder the desired reaction in subsequent steps. To minimize evaporation of the aqueous reagents from the specimen-containing slide a coverslip solution is applied in the slide stainer. For more detailed information on instrument operation, refer to the appropriate Ventana automated slide stainer Operator's Manual.", "Language": "en", "Country": "XG", "Code": "Principle" }, { "Name": "Product Purpose", "Value": "This antibody is intended for in vitro diagnostic (IVD) use.

Ventana^® Medical Systems’ (Ventana) FITC anti-C3 (complement 3) Primary Antibody is a goat derived polyclonal antibody labeled with fluorescein and specifically directed against human C3. This reagent should be used in conjunction with a panel of antibodies to aid in the identification of complement 3 in C3 target tissue (e.g., in the diagnosis of renal or dermal pathologies). FITC anti-C3 is intended for laboratory use to qualitatively stain sections of frozen tissue on a Ventana automated slide stainer.

The clinical interpretation of any staining, or the absence of staining, must be complemented by morphological studies and evaluation of proper controls. Evaluation must be made by a qualified pathologist within the context of the patient’s clinical history and other diagnostic tests.", "Language": "en", "Country": "XG", "Code": "Product Purpose" } ] } } ] }